Cargando…

基于高分辨UPLC-TOF-MS探讨A549/DDP与A549细胞内源性小分子代谢差异

BACKGROUND AND OBJECTIVE: Cisplatin acquired resistance is a vital problem in the chemotherapy of non-small cell lung cancer, which needs to be further addressed. In recent years, obtaining drug resistant cells from cell cultivation and serving for metabolomics research to find differential metaboli...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6105355/
https://www.ncbi.nlm.nih.gov/pubmed/30172262
http://dx.doi.org/10.3779/j.issn.1009-3419.2018.08.01
_version_ 1783349646318370816
collection PubMed
description BACKGROUND AND OBJECTIVE: Cisplatin acquired resistance is a vital problem in the chemotherapy of non-small cell lung cancer, which needs to be further addressed. In recent years, obtaining drug resistant cells from cell cultivation and serving for metabolomics research to find differential metabolites and get potential biomarkers, is a good reference for clinical research and cancer treatment. This study aimed to obtain metabolite information related to cisplatin resistance through metabolomics analysis. METHODS: Metabolites were extracted from A549 cells and cisplatin resistant A549/DDP cells, and ultraperformance liquid chromatography coupled with time of flight mass spectrometry was used to perform metabolomic analysis of endogenous molecules of the two cells and obtain metabolic differences. RESULTS: Through data analysis, 40 metabolites were identified as differential metabolites, mainly involving phospholipids, fatty acids, amino acids and metabolites related to energy metabolism. CONCLUSION: The drug resistance of A549/DDP cells may be caused by the changes of cell membrane structure and related metabolic pathways.
format Online
Article
Text
id pubmed-6105355
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-61053552018-08-27 基于高分辨UPLC-TOF-MS探讨A549/DDP与A549细胞内源性小分子代谢差异 Zhongguo Fei Ai Za Zhi 基础研究 BACKGROUND AND OBJECTIVE: Cisplatin acquired resistance is a vital problem in the chemotherapy of non-small cell lung cancer, which needs to be further addressed. In recent years, obtaining drug resistant cells from cell cultivation and serving for metabolomics research to find differential metabolites and get potential biomarkers, is a good reference for clinical research and cancer treatment. This study aimed to obtain metabolite information related to cisplatin resistance through metabolomics analysis. METHODS: Metabolites were extracted from A549 cells and cisplatin resistant A549/DDP cells, and ultraperformance liquid chromatography coupled with time of flight mass spectrometry was used to perform metabolomic analysis of endogenous molecules of the two cells and obtain metabolic differences. RESULTS: Through data analysis, 40 metabolites were identified as differential metabolites, mainly involving phospholipids, fatty acids, amino acids and metabolites related to energy metabolism. CONCLUSION: The drug resistance of A549/DDP cells may be caused by the changes of cell membrane structure and related metabolic pathways. 中国肺癌杂志编辑部 2018-08-20 /pmc/articles/PMC6105355/ /pubmed/30172262 http://dx.doi.org/10.3779/j.issn.1009-3419.2018.08.01 Text en 版权所有©《中国肺癌杂志》编辑部2018 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/
spellingShingle 基础研究
基于高分辨UPLC-TOF-MS探讨A549/DDP与A549细胞内源性小分子代谢差异
title 基于高分辨UPLC-TOF-MS探讨A549/DDP与A549细胞内源性小分子代谢差异
title_full 基于高分辨UPLC-TOF-MS探讨A549/DDP与A549细胞内源性小分子代谢差异
title_fullStr 基于高分辨UPLC-TOF-MS探讨A549/DDP与A549细胞内源性小分子代谢差异
title_full_unstemmed 基于高分辨UPLC-TOF-MS探讨A549/DDP与A549细胞内源性小分子代谢差异
title_short 基于高分辨UPLC-TOF-MS探讨A549/DDP与A549细胞内源性小分子代谢差异
title_sort 基于高分辨uplc-tof-ms探讨a549/ddp与a549细胞内源性小分子代谢差异
topic 基础研究
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6105355/
https://www.ncbi.nlm.nih.gov/pubmed/30172262
http://dx.doi.org/10.3779/j.issn.1009-3419.2018.08.01
work_keys_str_mv AT jīyúgāofēnbiànuplctofmstàntǎoa549ddpyǔa549xìbāonèiyuánxìngxiǎofēnzidàixièchàyì
AT jīyúgāofēnbiànuplctofmstàntǎoa549ddpyǔa549xìbāonèiyuánxìngxiǎofēnzidàixièchàyì
AT jīyúgāofēnbiànuplctofmstàntǎoa549ddpyǔa549xìbāonèiyuánxìngxiǎofēnzidàixièchàyì
AT jīyúgāofēnbiànuplctofmstàntǎoa549ddpyǔa549xìbāonèiyuánxìngxiǎofēnzidàixièchàyì
AT jīyúgāofēnbiànuplctofmstàntǎoa549ddpyǔa549xìbāonèiyuánxìngxiǎofēnzidàixièchàyì
AT jīyúgāofēnbiànuplctofmstàntǎoa549ddpyǔa549xìbāonèiyuánxìngxiǎofēnzidàixièchàyì